bluebird bio (NASDAQ:BLUE) delivered a profit and beat Wall Street’s expectations, AND beat the revenue expectation. The revenue beat is a positive sign to shareholders seeking high growth out of the company.
bluebird bio Earnings Cheat Sheet
Revenue: Rose 77.46% to $6.3 million from the year-earlier quarter.
Actual vs. Wall St. Expectations: bluebird bio reported adjusted EPS income of $2.13 per share. By that measure, the company beat the mean analyst estimate of $-0.35. It beat the average revenue estimate of $4.48 million.
Quoting Management: “bluebird has made substantial progress during the first half of 2013 both operationally and in the clinic,” stated Nick Leschly, Chief bluebird. “In June, we completed our initial public offering, strengthening our balance sheet and attracting a number of new shareholders. We are now focused on initiating two additional clinical trials in the second half of 2013, including our phase 2/3 CCALD study with Lenti-D.”
Key Stats (on next page)…
Revenue increased 457.52% from $1.13 million in the previous quarter.
Looking Forward: Analysts have a more negative outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings has fallen from $0 to a loss $0.22. For the current year, the average estimate has moved down from $0 to a loss of $1.14 over the last ninety days.
Stocks with improving earnings metrics are worthy of your extra attention. In fact, “E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our CHEAT SHEET investing framework for this very reason. Don’t waste another minute – click here and get our CHEAT SHEET stock picks now.
(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at] wallstcheatsheet.com)